Biblio

Found 30 results
[ Author(Asc)] Keyword Title Type Year
Filters: First Letter Of Last Name is V  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
V
A. Viswanathan, Creutzberg, C. L., Craighead, P., McCormack, M., Toita, T., Narayan, K., Reed, N. Simon, Long, H. J., Kim, H. - J., Marth, C., Lindegaard, J. C., Cerrotta, A., Small, W., and Trimble, E. L., International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG)., Int J Radiat Oncol Biol Phys, vol. 82, no. 1, pp. 250-5, 2012.
J. B. Vermorken, Consolidation therapy in patients with advanced ovarian cancer., Eur J Gynaecol Oncol, vol. 15, no. 1, pp. 7-13, 1994.
J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., and Verheijen, R. H. M., Clinical trials in ovarian carcinoma: study methodology., Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.
J. B. Vermorken, The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review., Int J Gynecol Cancer, vol. 3, no. 3, pp. 129-142, 1993.
J. B. Vermorken, Harper, P. G., and Buyse, M., The role of anthracyclines in epithelial ovarian cancer., Ann Oncol, vol. 10 Suppl 1, pp. 43-50, 1999.
J. B. Vermorken, Huinink, W. W. ten Bok, Eisenhauer, E., Favalli, G., Belpomme, D., Conte, P. F., and Kaye, S. B., Advanced ovarian cancer. Carboplatin versus cisplatin., Ann Oncol, vol. 4 Suppl 4, pp. 41-8, 1993.
J. B. Vermorken, Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG)., Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 73-6, 2001.
J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., Verheijen, R. H. M., InterGroup, G. Cancer, ,, /NCRI, M. R. C., ,, -CTG, N. C. I. C., ,, -OVAR, A. G. O., and , Clinical trials in ovarian carcinoma: study methodology, Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.
J. B. Vermorken and Pecorelli, S., Clinical trials in patients with epithelial ovarian cancer: past, present and future., Eur J Surg Oncol, vol. 22, no. 5, pp. 455-66, 1996.
J. B. Vermorken, Optimal treatment for ovarian cancer: taxoids and beyond., Ann Oncol, vol. 11 Suppl 3, pp. 131-9, 2000.
J. B. Vermorken, Åvall-Lundqvist, E., Pfisterer, J., Bacon, M., ,, -OVAR, A. G. O., ,, -GCC, E. O. R. T. C., ,, ,, ,, ,, ,, -CTG, N. C. I. C., -US, N. C. I., ,, ,, and , The Gynecologic Cancer Intergroup (GCIG): History and current status, Ann Oncol, vol. 16 Suppl 8, pp. viii39-viii42, 2005.
J. B. Vermorken and Hoekman, K., Chemotherapy for gynecologic malignancies., Curr Opin Oncol, vol. 7, no. 5, pp. 457-65, 1995.
J. B. Vermorken, Åvall-Lundqvist, E., Pfisterer, J., and Bacon, M., The Gynecologic Cancer Intergroup (GCIG): history and current status., Ann Oncol, vol. 16 Suppl 8, pp. viii39-viii42, 2005.
J. B. Vermorken, The role of intraperitoneal chemotherapy in epithelial ovarian cancer., Int J Gynecol Cancer, vol. 10, no. S1, pp. 26-32, 2000.
J. B. Vermorken, Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG), Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 73-6, 2001.
L. Verleye, Coens, C., Amant, F., van der Burg, M. E. L., Johnson, N., Verheijen, R. H. M., Coronado, P., Reed, N. Simon, RJ, P., and Vergote, I. B., Predictive value of C-ERB2 for response to first-line chemotherapy in 206 advanced-stage ovarian cancer patients. , Int Gyn Cancer Soc, 2008.
L. Verleye, PB, O., Coens, C., Amant, F., Kristensen, G. B., Tropé, C. G., Johnson, N., HC, vanDoorn, Reed, N. Simon, Verheijen, R. H. M., Hoskins, P., Trimbos, B., B, M., Mendiola, C., J, vander Velden, Eisenhauer, E., and Vergote, I. B., Quality of surgery in advanced ovarian cancer: Audit of original surgery reports of 442 patients from the neoadjuvant trial. , Int Gyn Cancer Soc, 2008.
I. B. Vergote, Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. Benedetti, Kenter, G. G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G. C. E., Pecorelli, S., and Reed, N. Simon, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer., N Engl J Med, vol. 363, no. 10, pp. 943-53, 2010.
I. B. Vergote, Rustin, G. J. S., Eisenhauer, E., Kristensen, G. B., Pujade-Lauraine, E., Parmar, M. K. B., Friedlander, M. Leonard, Jakobsen, A., and Vermorken, J. B., Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup., J Natl Cancer Inst, vol. 92, no. 18, pp. 1534-5, 2000.
I. B. Vergote, Calvert, A. H., Kania, M., Kaiser, C., Zimmermann, A. Hayden, and Sehouli, J., A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer, Eur J Cancer, vol. 45, pp. 1415-23, 2009.
I. B. Vergote, Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C. B., Colombo, N., Lesoin, A., Casado, A., Reinthaller, A., Green, J. A., Buck, M., Ray-Coquard, I., Ferrero, A., Favier, L., Reed, N. Simon, Curé, H., and Pujade-Lauraine, E., Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC GCG, and GCIG study., J Clin Oncol, vol. 32, no. 4, pp. 320-6, 2014.
I. B. Vergote, Organization and ethical aspects of randomized trials in gynecologic oncology, Verh K Acad Geneeskd Belg, vol. 62, pp. 385-95; discussion 395-8, 2000.
G. F. Vercellino, Erdemoglu, E., Lichtenberg, P., Muallem, M. Z., Richter, R., Abu-Rustum, N. R., Plante, M., Lécuru, F., Greggi, S., Monk, B. J., Sagae, S., Denkert, C., Keller, M., Alhakeem, M., Hellriegel, M., Dückelmann, A. M., Chiantera, V., and Sehouli, J., A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer., Arch Gynecol Obstet, 2019.
P. A. Vasey, Atkinson, R. J., Osborne, R., Parkin, D., Symonds, R., Paul, J., Lewsley, L. A., Coleman, R. L., Reed, N. Simon, Kaye, S. B., and Rustin, G. J. S., SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer, Br J Cancer, vol. 94, pp. 62-8, 2006.
P. A. Vasey, Jayson, G. C., Gordon, A., Gabra, H., Coleman, R. L., Atkinson, R. J., Parkin, D., Paul, J., Hay, A., Kaye, S. B., and Group, S. Gynaecolog, Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma, J Natl Cancer Inst, vol. 96, pp. 1682-91, 2004.

Pages